Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. META
9. AMC
10. COHR

Go back to Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1164.89 +11.96 (1.04%)
Previous Close $1152.93    52 Week High $88.16 
Open $1144.49    52 Week Low $67.88 
Day High $1170.90    P/E 269.65 
Day Low $1134.41    EPS $4.32 
Volume 2,476,699